COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

1 . A method for treating a patient having an inflammatory disorder, said method comprising administering to said patient (i) a tricyclic antidepressant; and (ii) a corticosteroid, wherein the drugs (i) and (ii) are administered simultaneously or within 14 days of each other, in amounts sufficient to reduce or inhibit inflammation in said patient, wherein said tricyclic antidepressant and/or said corticosteroid is administered rectally.

2 . The method of claim 1 , wherein said tricyclic antidepressant is amoxapine, 8-hydroxyamoxapine, 7-hydroxyamoxapine, loxapine, loxapine succinate, loxapine hydrochloride, 8-hydroxyloxapine, amitriptyline, clomipramine, doxepin, imipramine, trimipramine, desipramine, nortriptyline, clothiapine, perlapine, fluperlapine, or protriptyline.

3 . The method of claim 1 , wherein said corticosteroid is dexamethasone, betamethasone, triamcinolone, triamcinolone acetonide, triamcinolone diacetate, triamcinolone hexacetonide, beclomethasone, dipropionate, beclomethasone dipropionate monohydrate, flumethasone pivalate, diflorasone diacetate, fluocinolone acetonide, fluorometholone, fluorometholone acetate, clobetasol propionate, desoximethasone, fluoxymesterone, fluprednisolone, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydrocortisone cypionate, hydrocortisone probutate, hydrocortisone valerate, cortisone acetate, paramethasone acetate, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, prednisolone, prednisolone acetate, prednisolone sodium phosphate, prednisolone tebutate, clocortolone pivalate, flucinolone, dexamethasone 21-acetate, betamethasone 17-valerate, isoflupredone, 9-fluorocortisone, 6-hydroxydexamethasone, dichlorisone, meclorisone, flupredidene, doxibetasol, halopredone, halometasone, clobetasone, diflucortolone, isoflupredone acetate, fluorohydroxyandrostenedione, beclomethasone, flumethasone, diflorasone, fluocinolone, clobetasol, cortisone, paramethasone, clocortolone, prednisolone 21-hemisuccinate free acid, prednisolone metasulphobenzoate, prednisolone terbutate, or triamcinolone acetonide 21-palmitate.

4 . The method of claim 3 , wherein said corticosteroid is prednisolone or prednisone.

5 . The method of claim 1 , wherein said tricyclic antidepressant is administered in a dosage amount equivalent to 1-600 milligrams of amoxapine.

6 . The method of claim 1 , wherein said tricyclic antidepressant and said corticosteroid are administered within ten days of each other.

7 . The method of claim 6 , wherein tricyclic antidepressant and said corticosteroid are administered within five days of each other.

8 . The method of claim 7 , wherein tricyclic antidepressant and said corticosteroid are administered within twenty-four hours of each other.

9 . The method of claim 8 , wherein tricyclic antidepressant and said corticosteroid are administered simultaneously.

10 . The method of claim 1 , wherein said inflammatory disorder is an immunoinflammatory disorder.

11 . The method of claim 10 , wherein said immunoinflammatory disorder is rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn's disease, or stroke induced brain cell death.

12 . The method of claim 1 , wherein said inflammatory disorder is an autoimmune disease.

13 . The method of claim 12 , wherein said autoimmune disease is asthma, multiple sclerosis, type I diabetes, systemic lupus erythematosus, scleroderma, systemic sclerosis, or Sjögren's syndrome.

14 . The method of claim 1 , wherein said tricyclic antidepressant is amoxapine and said corticosteroid is prednisolone or prednisone.

15 . A method for treating a patient having an inflammatory disorder, said method comprising administering to said patient a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the drugs (i) amoxapine and (ii) prednisolone or prednisone, at dosages that together reduce or inhibit inflammation in said person wherein said composition is administered rectally.

16 . The method of claim 15 , wherein said inflammatory disorder is rheumatoid arthritis.

17 . The method of claim 15 , wherein said inflammatory disorder is psoriasis.

18 . The method of claim 15 , wherein said inflammatory disorder is ulcerative colitis.

19 . The method of claim 15 , wherein said inflammatory disorder is Crohn's disease.